Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Liu, Xinxin ^a   Wang, Xin ^a   Duan, Xiaoru ^a   Poorun, Devesh ^a   Xu, Juntao ^a   Zhang, Song ^a   Gan, Lu ^a   He, Mengwen ^a   Zhu, Ke ^a   Ming, Zhangyin ^a   Hu, Feng ^a   Chen, Hongxiang ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5(S),6(R)-7-TRIHYDROXYHEPTANOIC ACID, METHYL ESTER; AUTACOID; CYTOKINE; HEPTANOIC ACID DERIVATIVE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOXIN; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR 4;

ANIMAL; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; METABOLISM; MOUSE; PROTEIN TRANSPORT; PSORIASIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HMGB1 PROTEIN; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; KERATINOCYTES; LIPOXINS; MICE; PROTEIN TRANSPORT; PSORIASIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 85026830797     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07485-1     Document Type: Article

References (38)

1. Goff, K. L. et al. The Global Burden of Psoriatic Skin Disease. Br J Dermatol. 172, 1665-1668 (2015).
2. Anderson, K. S. et al. Elevation of Serum Epidermal Growth Factor and Interleukin 1 Receptor Antagonist in Active Psoriasis Vulgaris. Br J Dermatol. 163, 1085-1089 (2010).
3. He, Z. et al. Elevated Serum Levels of Interleukin 21 are Associated with Disease Severity in Patients with Psoriasis. Br J Dermatol. 167, 191-193 (2012).
4. West, K. L., Castellini, M. A., Duncan, M. K. & Bustin, M. Chromosomal Proteins HMGN3a and HMGN3b Regulate the Expression of Glycine Transporter 1. Mol Cell Biol. 24, 3747-3756 (2004).
5. Stros, M., Ozaki, T., Bacikova, A., Kageyama, H. & Nakagawara, A. HMGB1 and HMGB2 Cell-Specifically Down-Regulate the P53-and P73-Dependent Sequence-Specific Transactivation From the Human Bax Gene Promoter. J Biol Chem. 277, 7157-7164 (2002).
6. Wang, H. et al. HMG-1 as a Late Mediator of Endotoxin Lethality in Mice. Science. 285, 248-251 (1999).
7. Lotze, M. T. & Tracey, K. J. High-Mobility Group Box 1 Protein (HMGB1): Nuclear Weapon in the Immune Arsenal. Nat Rev Immunol. 5, 331-342 (2005).
8. Bonaldi, T. et al. Monocytic Cells Hyperacetylate Chromatin Protein HMGB1 to Redirect It Towards Secretion. Embo J. 22, 5551-5560 (2003).
9. Dumitriu, I. E. et al. Release of High Mobility Group Box 1 by Dendritic Cells Controls T Cell Activation Via the Receptor for Advanced Glycation End Products. J Immunol. 174, 7506-7515 (2005).
10. Schaper, F., Westra, J. & Bijl, M. Recent Developments in the Role of High-Mobility Group Box 1 in Systemic Lupus Erythematosus. Mol Med. 20, 72-79 (2014).
11. Magna, M. & Pisetsky, D. S. The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases. Mol Med. 20, 138-146 (2014).
12. Bergmann, C. et al. High Mobility Group Box 1 is Increased in the Sera of Psoriatic Patients with Disease Progression. J Eur Acad Dermatol Venereol. 30, 435-441 (2016).
13. Chen, T. et al. Increased HMGB1 Serum Levels and Altered HMGB1 Expression in Patients with Psoriasis Vulgaris. Arch Dermatol Res. 305, 263-267 (2013).
14. Zhang, W. et al. Proinflammatory Effect of HMGB1 On Keratinocytes: An Autocrine Mechanism Underlying Psoriasis Development. J Pathol., doi: 10.1002/path.4848 (2016).
15. Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving Inflammation: Dual Anti-Inflammatory and Pro-Resolution Lipid Mediators. Nat Rev Immunol. 8, 349-361 (2008).
16. Serhan, C. N. Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annu Rev Immunol. 25, 101-137 (2007).
17. Hu, F. et al. Lipoxin A4 Inhibits Proliferation and Inflammatory Cytokine/Chemokine Production of Human Epidermal Keratinocytes Associated with the ERK1/2 and NF-kappaB Pathways. J Dermatol Sci. 78, 181-188 (2015).
18. Hu, F. et al. Lipoxin A4 Inhibits Lipopolysaccharide-Induced Production of Inflammatory Cytokines in Keratinocytes by Up-Regulating SOCS2 and Down-Regulating TRAF6. J Huazhong Univ Sci Technolog Med Sci. 35, 426-431 (2015).
19. Conte, F. P. et al. LipoxinA(4) Attenuates Zymosan-Induced Arthritis by Modulating Endothelin-1 and its Effects. Br J Pharmacol. 161, 911-924 (2010).
20. Lee, T. H., Lympany, P., Crea, A. E. & Spur, B. W. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 180, 1416-1421 (1991).
21. Zhang, L. et al. Protective Effects of BML-111, a LipoxinA(4) Receptor Agonist, On Carbon Tetrachloride-Induced Liver Injury in Mice. Hepatol Res. 37, 948-956 (2007).
22. Hernandez-Pando, R. et al. The Role of High Mobility Group Box 1 Protein (Hmgb1) in the Immunopathology of Experimental Pulmonary Tuberculosis. Plos One. 10, e133200 (2015).
23. van der Fits, L. et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice is Mediated Via the IL-23/IL-17 Axis. J Immunol. 182, 5836-5845 (2009).
24. Ullah, M. A. et al. Receptor for Advanced Glycation End Products and its Ligand High-Mobility Group Box-1 Mediate Allergic Airway Sensitization and Airway Inflammation. J Allergy Clin Immunol. 134, 440-450 (2014).
25. Milutinovic, P. S., Alcorn, J. F., Englert, J. M., Crum, L. T. & Oury, T. D. The Receptor for Advanced Glycation End Products is a Central Mediator of Asthma Pathogenesis. Am J Pathol. 181, 1215-1225 (2012).
26. Bonaldi, T. et al. Monocytic Cells Hyperacetylate Chromatin Protein Hmgb1 to Redirect It Towards Secretion. Embo J. 22, 5551-5560 (2003).
27. Lu, B. et al. Jak/Stat1 Signaling Promotes Hmgb1 Hyperacetylation and Nuclear Translocation. Proc Natl Acad Sci USA 111, 3068-3073 (2014).
28. Lin, F. et al. Treatment of LipoxinA(4) and its Analogue On Low-Dose Endotoxin Induced Preeclampsia in Rat and Possible Mechanisms. Reprod Toxicol. 34, 677-685 (2012).
29. Hao, H. et al. Lipoxin A4 and its Analog Suppress Hepatocellular Carcinoma Via Remodeling Tumor Microenvironment. Cancer Lett. 309, 85-94 (2011).
30. Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis. N Engl J Med. 361, 496-509 (2009).
31. Asadullah, K., Docke, W. D., Volk, H. D. & Sterry, W. The Pathophysiological Role of Cytokines in Psoriasis. Drugs Today (Barc). 35, 913-924 (1999).
32. Tadie, J. M. et al. Toll-Like Receptor 4 Engagement Inhibits Adenosine 5′-Monophosphate-Activated Protein Kinase Activation through a High Mobility Group Box 1 Protein-Dependent Mechanism. Mol Med. 18, 659-668 (2012).
33. Park, J. S. et al. Involvement of Toll-Like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein. J Biol Chem. 279, 7370-7377 (2004).
34. Dumitriu, I. E., Baruah, P., Bianchi, M. E., Manfredi, A. A. & Rovere-Querini, P. Requirement of HMGB1 and RAGE for the Maturation of Human Plasmacytoid Dendritic Cells. Eur J Immunol. 35, 2184-2190 (2005).
35. Karuppagounder, V. et al. Modulation of HMGB1 Translocation and RAGE/NFkappaB Cascade by Quercetin Treatment Mitigates Atopic Dermatitis in NC/Nga Transgenic Mice. Exp Dermatol. 24, 418-423 (2015).
36. Nogueira-Machado, J. A., Volpe, C. M., Veloso, C. A. & Chaves, M. M. HMGB1, TLR and RAGE: A Functional Tripod that Leads to Diabetic Inflammation. Expert Opin Ther Targets. 15, 1023-1035 (2011).
37. Ipaktchi, K. et al. Topical p38MAPK Inhibition Reduces Dermal Inflammation and Epithelial Apoptosis in Burn Wounds. Shock. 26, 201-209 (2006).
38. Riehl, A. et al. Identification of the Rage-dependent Gene Regulatory Network in a Mouse Model of Skin Inflammation. BMC Genomics. 11, 537 (2010).